科兴制药
(688136)
| 流通市值：74.57亿 | | | 总市值：74.57亿 |
| 流通股本：2.01亿 | | | 总股本：2.01亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,147,639,140.97 | 700,464,766.25 | 353,559,464.74 | 1,406,925,448.3 |
| 营业收入 | 1,147,639,140.97 | 700,464,766.25 | 353,559,464.74 | 1,406,925,448.3 |
| 二、营业总成本 | 1,070,420,698.89 | 653,551,426.35 | 323,281,678.19 | 1,344,390,356.12 |
| 营业成本 | 418,404,980.55 | 255,257,060.07 | 113,578,376.51 | 440,527,341.44 |
| 税金及附加 | 9,852,036.04 | 6,256,692.48 | 3,223,738.23 | 12,229,811.75 |
| 销售费用 | 420,667,831.17 | 254,953,408.24 | 142,770,592.45 | 596,765,436.43 |
| 管理费用 | 65,714,628.24 | 43,443,007.96 | 19,244,051.06 | 85,962,747.7 |
| 研发费用 | 132,621,448.46 | 81,662,554.29 | 37,206,245.26 | 168,050,430.04 |
| 财务费用 | 23,159,774.43 | 11,978,703.31 | 7,258,674.68 | 40,854,588.76 |
| 其中:利息费用 | 31,019,463.49 | 20,615,665.54 | 10,452,112.31 | 43,571,269.16 |
| 其中:利息收入 | 2,253,240.28 | 1,473,426.1 | 722,885.78 | 3,626,754.45 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 15,439,757.31 | 15,439,757.31 | - | -29,188,617.47 |
| 加:投资收益 | 27,187,204.78 | 23,176,579.52 | 3,803,273.11 | 9,325,939.69 |
| 资产处置收益 | 953,403.74 | -114,723.4 | 19,269.96 | 77,059.28 |
| 资产减值损失(新) | -2,050,530.99 | -978,079.61 | -429,850.07 | -3,669,050.48 |
| 信用减值损失(新) | -5,275,579.45 | -530,068.05 | -1,507,370.08 | -1,609,253.69 |
| 其他收益 | 4,201,064.44 | 2,304,815.88 | 1,954,838.54 | 25,729,346.04 |
| 四、营业利润 | 117,673,761.91 | 86,211,621.55 | 34,117,948.01 | 63,200,515.55 |
| 加:营业外收入 | 488,448.84 | 276,084.45 | 6,503.06 | 197,345.11 |
| 减:营业外支出 | 2,823,499.29 | 2,358,755.8 | 2,338,951.16 | 6,495,252.51 |
| 五、利润总额 | 115,338,711.46 | 84,128,950.2 | 31,785,499.91 | 56,902,608.15 |
| 减:所得税费用 | 6,236,575.12 | 5,166,478.14 | 6,934,393.15 | 29,854,052.75 |
| 六、净利润 | 109,102,136.34 | 78,962,472.06 | 24,851,106.76 | 27,048,555.4 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 109,102,136.34 | 78,962,472.06 | 24,851,106.76 | 27,048,555.4 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 111,262,991.17 | 80,344,468.24 | 25,577,232.91 | 31,480,893.13 |
| 少数股东损益 | -2,160,854.83 | -1,381,996.18 | -726,126.15 | -4,432,337.73 |
| 扣除非经常损益后的净利润 | 70,446,588.68 | 45,279,121.97 | 22,603,851.46 | 35,254,315.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.56 | 0.41 | 0.13 | 0.16 |
| (二)稀释每股收益 | 0.56 | 0.4 | 0.13 | 0.16 |
| 八、其他综合收益 | -80,087.15 | -25,544.5 | -3,532.56 | 1,119,696.97 |
| 归属于母公司股东的其他综合收益 | -80,087.15 | -25,544.5 | -3,532.56 | 1,119,696.97 |
| 九、综合收益总额 | 109,022,049.19 | 78,936,927.56 | 24,847,574.2 | 28,168,252.37 |
| 归属于母公司股东的综合收益总额 | 111,182,904.02 | 80,318,923.74 | 25,573,700.35 | 32,600,590.1 |
| 归属于少数股东的综合收益总额 | -2,160,854.83 | -1,381,996.18 | -726,126.15 | -4,432,337.73 |
| 公告日期 | 2025-10-30 | 2025-08-23 | 2025-04-28 | 2025-04-11 |
| 审计意见(境内) | | | | 标准无保留意见 |